5 Nov
2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Mammoth Biosciences' $650 million licensing deal with Vertex Pharmaceuticals highlights the value of CRISPR innovations beyond Cas9

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth